{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:57:15Z","timestamp":1793710635599,"version":"4.6.1"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA241191"],"award-info":[{"award-number":["R01 CA241191"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogenesis"],"DOI":"10.1038\/s41389-026-00632-2","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:52:22Z","timestamp":1780509142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Anti-apoptotic BCL-2 family proteins: from regulatory networks to therapeutic targeting"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9129-4125","authenticated-orcid":false,"given":"Zhe","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3204-8689","authenticated-orcid":false,"given":"Mutian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"632_CR1","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/s41418-023-01153-w","volume":"30","author":"I Vitale","year":"2023","unstructured":"Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Adam D, et al. Apoptotic cell death in disease\u2014Current understanding of the NCCD 2023. Cell Death Differ. 2023;30:1097\u2013154.","journal-title":"Cell Death Differ"},{"key":"632_CR2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.trecan.2023.02.001","volume":"9","author":"K H\u00e4nggi","year":"2023","unstructured":"H\u00e4nggi K, Ruffell B. Cell death, therapeutics, and the immune response in cancer. Trends Cancer. 2023;9:381\u201396.","journal-title":"Trends Cancer"},{"key":"632_CR3","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1101\/gad.13.24.3179","volume":"13","author":"J Rodriguez","year":"1999","unstructured":"Rodriguez J, Lazebnik Y. Caspase-9 and APAF-1 form an active holoenzyme. Genes Dev. 1999;13:3179\u201384.","journal-title":"Genes Dev"},{"key":"632_CR4","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1126\/science.1115035","volume":"311","author":"SA Lakhani","year":"2006","unstructured":"Lakhani SA, Masud A, Kuida K, Porter GA, Booth CJ, Mehal WZ, et al. Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science. 2006;311:847\u201351.","journal-title":"Science"},{"key":"632_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","volume":"10","author":"M Vogler","year":"2025","unstructured":"Vogler M, Braun Y, Smith VM, Westhoff M-A, Pereira RS, Pieper NM, et al. The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy. Signal Transduct Target Ther. 2025;10:91.","journal-title":"Signal Transduct Target Ther"},{"key":"632_CR6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/369321a0","volume":"369","author":"XM Yin","year":"1994","unstructured":"Yin XM, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature. 1994;369:321\u20133.","journal-title":"Nature"},{"key":"632_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.molcel.2010.01.025","volume":"37","author":"JE Chipuk","year":"2010","unstructured":"Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 Family Reunion. Mol Cell. 2010;37:299\u2013310.","journal-title":"Mol Cell"},{"key":"632_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","volume":"9","author":"M Certo","year":"2006","unstructured":"Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9:351\u201365.","journal-title":"Cancer Cell"},{"key":"632_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311\u201322.","journal-title":"N Engl J Med"},{"key":"632_CR10","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","volume":"9","author":"P Blombery","year":"2019","unstructured":"Blombery P, Anderson MA, Gong J-N, Thijssen R, Birkinshaw RW, Thompson ER, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019;9:342\u201353.","journal-title":"Cancer Discov"},{"key":"632_CR11","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","volume":"24","author":"DA Pollyea","year":"2018","unstructured":"Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018;24:1859\u201366.","journal-title":"Nat Med"},{"key":"632_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18372-1","volume":"11","author":"E Munkhbaatar","year":"2020","unstructured":"Munkhbaatar E, Dietzen M, Agrawal D, Anton M, Jesinghaus M, Boxberg M, et al. MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. Nat Commun. 2020;11:4527.","journal-title":"Nat Commun"},{"key":"632_CR13","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/sj.leu.2403784","volume":"19","author":"S Wuill\u00e8me-Toumi","year":"2005","unstructured":"Wuill\u00e8me-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H, et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia. 2005;19:1248\u201352.","journal-title":"Leukemia"},{"key":"632_CR14","doi-asserted-by":"publisher","first-page":"12492","DOI":"10.1073\/pnas.1507491112","volume":"112","author":"H Park","year":"2015","unstructured":"Park H, Cho S-Y, Kim H, Na D, Han JY, Chae J, et al. Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer. Proc Natl Acad Sci USA. 2015;112:12492\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"632_CR15","doi-asserted-by":"publisher","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","volume":"7","author":"JD Leverson","year":"2015","unstructured":"Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med. 2015;7:279ra40.","journal-title":"Sci Transl Med"},{"key":"632_CR16","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.1073\/pnas.1205575110","volume":"110","author":"R Haq","year":"2013","unstructured":"Haq R, Yokoyama S, Hawryluk EB, J\u00f6nsson GB, Frederick DT, McHenry K, et al. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci USA. 2013;110:4321\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"632_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"632_CR18","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","volume":"25","author":"S Khan","year":"2019","unstructured":"Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25:1938\u201347.","journal-title":"Nat Med"},{"key":"632_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ado7120","volume":"10","author":"AS Judd","year":"2024","unstructured":"Judd AS, Bawa B, Buck WR, Tao Z-F, Li Y, Mitten MJ, et al. BCL-XL-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors. Sci Adv. 2024;10:eado7120.","journal-title":"Sci Adv"},{"key":"632_CR20","doi-asserted-by":"publisher","first-page":"7836","DOI":"10.1021\/acs.jmedchem.4c00027","volume":"67","author":"Y Guo","year":"2024","unstructured":"Guo Y, Xue H, Hu N, Liu Y, Sun H, Yu D, et al. Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2. J Med Chem. 2024;67:7836\u201358.","journal-title":"J Med Chem"},{"key":"632_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10363-1","volume":"10","author":"RW Birkinshaw","year":"2019","unstructured":"Birkinshaw RW, Gong J, Luo CS, Lio D, White CA, Anderson MA, et al. Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. Nat Commun. 2019;10:2385.","journal-title":"Nat Commun"},{"key":"632_CR22","doi-asserted-by":"publisher","first-page":"4844","DOI":"10.1158\/1078-0432.CCR-24-0028","volume":"30","author":"P Desai","year":"2024","unstructured":"Desai P, Lonial S, Cashen A, Kamdar M, Flinn I, O\u2019Brien S, et al. A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed\/Refractory Hematologic Malignancies. Clin Cancer Res. 2024;30:4844\u201355.","journal-title":"Clin Cancer Res"},{"key":"632_CR23","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","volume":"128","author":"KD Mason","year":"2007","unstructured":"Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128:1173\u201386.","journal-title":"Cell"},{"key":"632_CR24","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1182\/blood-2011-04-347849","volume":"118","author":"SM Schoenwaelder","year":"2011","unstructured":"Schoenwaelder SM, Jarman KE, Gardiner EE, Hua M, Qiao J, White MJ, et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood. 2011;118:1663\u201374.","journal-title":"Blood"},{"key":"632_CR25","doi-asserted-by":"publisher","first-page":"7342","DOI":"10.1038\/sj.onc.1204926","volume":"20","author":"SD Catz","year":"2001","unstructured":"Catz SD, Johnson JL. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene. 2001;20:7342\u201351.","journal-title":"Oncogene"},{"key":"632_CR26","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1093\/nar\/gkr023","volume":"39","author":"F Gong","year":"2011","unstructured":"Gong F, Sun L, Wang Z, Shi J, Li W, Wang S, et al. The BCL2 gene is regulated by a special AT-rich sequence binding protein 1-mediated long range chromosomal interaction between the promoter and the distal element located within the 3\u2032-UTR. Nucleic Acids Res. 2011;39:4640\u201352.","journal-title":"Nucleic Acids Res"},{"key":"632_CR27","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1128\/MCB.16.10.5546","volume":"16","author":"BE Wilson","year":"1996","unstructured":"Wilson BE, Mochon E, Boxer LM. Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol. 1996;16:5546\u201356.","journal-title":"Mol Cell Biol"},{"key":"632_CR28","doi-asserted-by":"publisher","first-page":"13944","DOI":"10.1073\/pnas.0506654102","volume":"102","author":"A Cimmino","year":"2005","unstructured":"Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 2005;102:13944\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"632_CR29","doi-asserted-by":"publisher","first-page":"10855","DOI":"10.1074\/jbc.M309111200","volume":"279","author":"TK Sengupta","year":"2004","unstructured":"Sengupta TK, Bandyopadhyay S, Fernandes DJ, Spicer EK. Identification of Nucleolin as an AU-rich Element Binding Protein Involved in bcl-2 mRNA Stabilization. J Biol Chem. 2004;279:10855\u201363.","journal-title":"J Biol Chem"},{"key":"632_CR30","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1158\/1541-7786.MCR-08-0476","volume":"7","author":"D Ishimaru","year":"2009","unstructured":"Ishimaru D, Ramalingam S, Sengupta TK, Bandyopadhyay S, Dellis S, Tholanikunnel BG, et al. Regulation of Bcl-2 expression by HuR in HL60 leukemia cells and A431 carcinoma cells. Mol Cancer Res. 2009;7:1354\u201366.","journal-title":"Mol Cancer Res"},{"key":"632_CR31","doi-asserted-by":"publisher","first-page":"e102625","DOI":"10.1371\/journal.pone.0102625","volume":"9","author":"A Zekavati","year":"2014","unstructured":"Zekavati A, Nasir A, Alcaraz A, Aldrovandi M, Marsh P, Norton JD, et al. Post-transcriptional regulation of BCL2 mRNA by the RNA-binding protein ZFP36L1 in malignant B cells. PLoS One. 2014;9:e102625.","journal-title":"PLoS One"},{"key":"632_CR32","first-page":"1609","volume":"58","author":"S Haldar","year":"1998","unstructured":"Haldar S, Basu A, Croce CM. Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. Cancer Res. 1998;58:1609\u201315.","journal-title":"Cancer Res"},{"key":"632_CR33","doi-asserted-by":"publisher","first-page":"21155","DOI":"10.1074\/jbc.274.30.21155","volume":"274","author":"DG Kirsch","year":"1999","unstructured":"Kirsch DG, Doseff A, Chau BN, Lim DS, de Souza-Pinto NC, Hansford R, et al. Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J Biol Chem. 1999;274:21155\u201361.","journal-title":"J Biol Chem"},{"key":"632_CR34","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.1242\/jcs.00829","volume":"116","author":"MJ Thomenius","year":"2003","unstructured":"Thomenius MJ, Distelhorst CW. Bcl-2 on the endoplasmic reticulum: protecting the mitochondria from a distance. J Cell Sci. 2003;116:4493\u20139.","journal-title":"J Cell Sci"},{"key":"632_CR35","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2004.12.030","volume":"17","author":"L Chen","year":"2005","unstructured":"Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17:393\u2013403.","journal-title":"Mol Cell"},{"key":"632_CR36","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.molcel.2005.02.003","volume":"17","author":"T Kuwana","year":"2005","unstructured":"Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR, et al. BH3 domains of BH3-only proteins differentially regulate bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell. 2005;17:525\u201335.","journal-title":"Mol Cell"},{"key":"632_CR37","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0092-8674(00)81013-2","volume":"98","author":"M Socolovsky","year":"1999","unstructured":"Socolovsky M, Fallon AEJ, Wang S, Brugnara C, Lodish HF. Fetal anemia and apoptosis of red cell progenitors in Stat5a\u2212\/\u22125b\u2212\/\u2212 Mice. Cell. 1999;98:181\u201391.","journal-title":"Cell"},{"key":"632_CR38","doi-asserted-by":"publisher","first-page":"9136","DOI":"10.1073\/pnas.96.16.9136","volume":"96","author":"HH Lee","year":"1999","unstructured":"Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1\/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci USA. 1999;96:9136\u201341.","journal-title":"Proc Natl Acad Sci USA"},{"key":"632_CR39","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/s41418-020-00692-w","volume":"28","author":"M Haselager","year":"2021","unstructured":"Haselager M, Thijssen R, West C, Young L, Van Kampen R, Willmore E, et al. Regulation of Bcl-XL by non-canonical NF-\u03baB in the context of CD40-induced drug resistance in CLL. Cell Death Differ. 2021;28:1658\u201368.","journal-title":"Cell Death Differ"},{"key":"632_CR40","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1074-7613(00)80011-4","volume":"10","author":"R Catlett-Falcone","year":"1999","unstructured":"Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10:105\u201315.","journal-title":"Immunity"},{"key":"632_CR41","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1038\/sj.onc.1203607","volume":"19","author":"CM Margue","year":"2000","unstructured":"Margue CM, Bernasconi M, Barr FG, Sch\u00e4fer BW. Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3\/FKHR. Oncogene. 2000;19:2921\u20139.","journal-title":"Oncogene"},{"key":"632_CR42","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12672-025-01783-1","volume":"16","author":"X Xue","year":"2025","unstructured":"Xue X, Li Z, Zhao J, Zhao Z, Li Z, Li Y, et al. Advances in the relationship between AP-1 and tumorigenesis, development and therapy resistance. Discov Oncol. 2025;16:61.","journal-title":"Discov Oncol"},{"key":"632_CR43","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/0092-8674(93)90508-N","volume":"74","author":"LH Boise","year":"1993","unstructured":"Boise LH, Gonz\u00e1lez-Garc\u00eda M, Postema CE, Ding L, Lindsten T, Turka LA, et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993;74:597\u2013608.","journal-title":"Cell"},{"key":"632_CR44","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.cell.2010.07.019","volume":"142","author":"MJ Moore","year":"2010","unstructured":"Moore MJ, Wang Q, Kennedy CJ, Silver PA. An alternative splicing network links cell-cycle control to apoptosis. Cell. 2010;142:625\u201336.","journal-title":"Cell"},{"key":"632_CR45","doi-asserted-by":"publisher","first-page":"12070","DOI":"10.1093\/nar\/gku922","volume":"42","author":"P Bielli","year":"2014","unstructured":"Bielli P, Bordi M, Di Biasio V, Sette C. Regulation of BCL-X splicing reveals a role for the polypyrimidine tract binding protein (PTBP1\/hnRNP I) in alternative 5\u2019 splice site selection. Nucleic Acids Res. 2014;42:12070\u201381.","journal-title":"Nucleic Acids Res"},{"key":"632_CR46","doi-asserted-by":"publisher","first-page":"11239","DOI":"10.1093\/nar\/gkad772","volume":"51","author":"R Le S\u00e9n\u00e9chal","year":"2023","unstructured":"Le S\u00e9n\u00e9chal R, Keruzor\u00e9 M, Quill\u00e9v\u00e9r\u00e9 A, Loa\u00ebc N, Dinh V-T, Reznichenko O, et al. Alternative splicing of BCL-x is controlled by RBM25 binding to a G-quadruplex in BCL-x pre-mRNA. Nucleic Acids Res. 2023;51:11239\u201357.","journal-title":"Nucleic Acids Res"},{"key":"632_CR47","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/0008-5472.CAN-07-1927","volume":"68","author":"J Zhang","year":"2008","unstructured":"Zhang J, Tsaprailis G, Bowden GT. Nucleolin stabilizes Bcl-X L messenger RNA in response to UVA irradiation. Cancer Res. 2008;68:1046\u201354.","journal-title":"Cancer Res"},{"key":"632_CR48","doi-asserted-by":"publisher","first-page":"7904","DOI":"10.1073\/pnas.0908441107","volume":"107","author":"Y Zhou","year":"2010","unstructured":"Zhou Y, Chen L, Barlogie B, Stephens O, Wu X, Williams DR, et al. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2\/AGO2. Proc Natl Acad Sci USA. 2010;107:7904\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"632_CR49","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0092-8674(03)00892-4","volume":"115","author":"BE Deverman","year":"2003","unstructured":"Deverman BE, Cook BL, Manson SR, Niederhoff RA, Langer EM, Rosov\u00e1 I, et al. Bcl-xL Deamidation Is a Critical Switch in the Regulation of the Response to DNA Damage. Cell. 2003;115:503.","journal-title":"Cell"},{"key":"632_CR50","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1182\/blood-2016-05-715961","volume":"128","author":"I Vardaki","year":"2016","unstructured":"Vardaki I, Sanchez C, Fonseca P, Olsson M, Chioureas D, Rassidakis G, et al. Caspase-3\u2013dependent cleavage of Bcl-xL in the stroma exosomes is required for their uptake by hematological malignant cells. Blood. 2016;128:2655\u201365.","journal-title":"Blood"},{"key":"632_CR51","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1073\/pnas.94.8.3668","volume":"94","author":"YT Hsu","year":"1997","unstructured":"Hsu YT, Wolter KG, Youle RJ. Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc Natl Acad Sci USA. 1997;94:3668\u201372.","journal-title":"Proc Natl Acad Sci USA"},{"key":"632_CR52","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1016\/j.celrep.2016.11.064","volume":"17","author":"J P\u00e9cot","year":"2016","unstructured":"P\u00e9cot J, Maillet L, Le Pen J, Vuillier C, Tr\u00e9cesson SdeC, F\u00e9tiveau A, et al. Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance. Cell Rep. 2016;17:3347\u201358.","journal-title":"Cell Rep"},{"key":"632_CR53","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1002\/j.1460-2075.1995.tb00246.x","volume":"14","author":"T Chittenden","year":"1995","unstructured":"Chittenden T, Flemington C, Houghton AB, Ebb RG, Gallo GJ, Elangovan B, et al. A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. EMBO J. 1995;14:5589\u201396.","journal-title":"EMBO J"},{"key":"632_CR54","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1002\/eji.201344238","volume":"44","author":"AR Shenoy","year":"2014","unstructured":"Shenoy AR, Kirschnek S, H\u00e4cker G. IL-15 regulates Bcl-2 family members Bim and Mcl-1 through JAK\/STAT and PI3K\/AKT pathways in T cells. Eur J Immunol. 2014;44:2500\u20137.","journal-title":"Eur J Immunol"},{"key":"632_CR55","doi-asserted-by":"publisher","first-page":"9336","DOI":"10.1074\/jbc.M411858200","volume":"280","author":"J-P Piret","year":"2005","unstructured":"Piret J-P, Minet E, Cosse J-P, Ninane N, Debacq C, Raes M, et al. Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis. J Biol Chem. 2005;280:9336\u201344.","journal-title":"J Biol Chem"},{"key":"632_CR56","doi-asserted-by":"publisher","first-page":"22551","DOI":"10.1074\/jbc.M702673200","volume":"282","author":"RM Fritsch","year":"2007","unstructured":"Fritsch RM, Schneider G, Saur D, Scheibel M, Schmid RM. Translational repression of MCL-1 couples stress-induced eIF2 alpha phosphorylation to mitochondrial apoptosis initiation. J Biol Chem. 2007;282:22551\u201362.","journal-title":"J Biol Chem"},{"key":"632_CR57","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/ncb3616","volume":"19","author":"X Wu","year":"2017","unstructured":"Wu X, Zhang L-S, Toombs J, Kuo Y-C, Piazza JT, Tuladhar R, et al. Extra-mitochondrial prosurvival BCL-2 proteins regulate gene transcription by inhibiting the SUFU tumour suppressor. Nat Cell Biol. 2017;19:1226\u201336.","journal-title":"Nat Cell Biol"},{"key":"632_CR58","doi-asserted-by":"publisher","first-page":"25255","DOI":"10.1074\/jbc.M909826199","volume":"275","author":"J Bae","year":"2000","unstructured":"Bae J, Leo CP, Hsu SY, Hsueh AJ. MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J Biol Chem. 2000;275:25255\u201361.","journal-title":"J Biol Chem"},{"key":"632_CR59","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1016\/j.febslet.2009.08.006","volume":"583","author":"J-H Kim","year":"2009","unstructured":"Kim J-H, Sim S-H, Ha H-J, Ko J-J, Lee K, Bae J. MCL-1ES, a novel variant of MCL-1, associates with MCL-1L and induces mitochondrial cell death. FEBS Lett. 2009;583:2758\u201364.","journal-title":"FEBS Lett"},{"key":"632_CR60","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1158\/1541-7786.MCR-10-0325","volume":"9","author":"N Filippova","year":"2011","unstructured":"Filippova N, Yang X, Wang Y, Gillespie GY, Langford C, King PH, et al. The RNA-binding protein HuR promotes glioma growth and treatment resistance. Mol Cancer Res. 2011;9:648\u201359.","journal-title":"Mol Cancer Res"},{"key":"632_CR61","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1172\/JCI80631","volume":"127","author":"F Ebner","year":"2017","unstructured":"Ebner F, Sedlyarov V, Tasciyan S, Ivin M, Kratochvill F, Gratz N, et al. The RNA-binding protein tristetraprolin schedules apoptosis of pathogen-engaged neutrophils during bacterial infection. J Clin Investig. 2017;127:2051\u201365.","journal-title":"J Clin Investig"},{"key":"632_CR62","doi-asserted-by":"publisher","first-page":"6133","DOI":"10.1038\/sj.onc.1210436","volume":"26","author":"JL Mott","year":"2007","unstructured":"Mott JL, Kobayashi S, Bronk SF, Gores GJ. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 2007;26:6133\u201340.","journal-title":"Oncogene"},{"key":"632_CR63","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.cell.2005.06.009","volume":"121","author":"Q Zhong","year":"2005","unstructured":"Zhong Q, Gao W, Du F, Wang X. Mule\/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell. 2005;121:1085\u201395.","journal-title":"Cell"},{"key":"632_CR64","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature09732","volume":"471","author":"H Inuzuka","year":"2011","unstructured":"Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 2011;471:104\u20139.","journal-title":"Nature"},{"key":"632_CR65","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1038\/emboj.2010.112","volume":"29","author":"ME Harley","year":"2010","unstructured":"Harley ME, Allan LA, Sanderson HS, Clarke PR. Phosphorylation of Mcl-1 by CDK1\u2013cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J. 2010;29:2407\u201320.","journal-title":"EMBO J"},{"key":"632_CR66","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature08646","volume":"463","author":"M Schwickart","year":"2010","unstructured":"Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature. 2010;463:103\u20137.","journal-title":"Nature"},{"key":"632_CR67","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/ncb2488","volume":"14","author":"RM Perciavalle","year":"2012","unstructured":"Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M, et al. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol. 2012;14:575\u201383.","journal-title":"Nat Cell Biol"},{"key":"632_CR68","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1083\/jcb.128.6.1173","volume":"128","author":"T Yang","year":"1995","unstructured":"Yang T, Kozopas KM, Craig RW. The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. J Cell Biol. 1995;128:1173\u201384.","journal-title":"J Cell Biol"},{"key":"632_CR69","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.molcel.2024.02.035","volume":"84","author":"T Wright","year":"2024","unstructured":"Wright T, Turnis ME, Grace CR, Li X, Brakefield LA, Wang Y-D, et al. Anti-apoptotic MCL-1 promotes long-chain fatty acid oxidation through interaction with ACSL1. Mol Cell. 2024;84:1338\u201353.e8.","journal-title":"Mol Cell"},{"key":"632_CR70","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1126\/science.adw1836","volume":"389","author":"K Brinkmann","year":"2025","unstructured":"Brinkmann K, McArthur K, Malelang S, Gibson L, Tee A, Elahee Doomun SN, et al. Relative importance of the anti-apoptotic versus apoptosis-unrelated functions of MCL-1 in vivo. Science. 2025;389:1003\u201311.","journal-title":"Science"},{"key":"632_CR71","doi-asserted-by":"publisher","first-page":"6384","DOI":"10.1074\/jbc.M707762200","volume":"283","author":"M Germain","year":"2008","unstructured":"Germain M, Milburn J, Duronio V. MCL-1 inhibits BAX in the absence of MCL-1\/BAX Interaction. J Biol Chem. 2008;283:6384\u201392.","journal-title":"J Biol Chem"},{"key":"632_CR72","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1172\/JCI29401","volume":"116","author":"R Piva","year":"2006","unstructured":"Piva R, Pellegrino E, Mattioli M, Agnelli L, Lombardi L, Boccalatte F, et al. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest. 2006;116:3171\u201382.","journal-title":"J Clin Invest"},{"key":"632_CR73","doi-asserted-by":"publisher","first-page":"e2103","DOI":"10.1038\/cddis.2016.23","volume":"7","author":"J Vier","year":"2016","unstructured":"Vier J, Groth M, Sochalska M, Kirschnek S. The anti-apoptotic Bcl-2 family protein A1\/Bfl-1 regulates neutrophil survival and homeostasis and is controlled via PI3K and JAK\/STAT signaling. Cell Death Dis. 2016;7:e2103.","journal-title":"Cell Death Dis"},{"key":"632_CR74","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/cdd.2011.158","volume":"19","author":"M Vogler","year":"2012","unstructured":"Vogler M. BCL2A1: the underdog in the BCL2 family. Cell Death Differ. 2012;19:67\u201374.","journal-title":"Cell Death Differ"},{"key":"632_CR75","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41418-018-0169-5","volume":"26","author":"L Lionnard","year":"2019","unstructured":"Lionnard L, Duc P, Brennan MS, Kueh AJ, Pal M, Guardia F, et al. TRIM17 and TRIM28 antagonistically regulate the ubiquitination and anti-apoptotic activity of BCL2A1. Cell Death Differ. 2019;26:902\u201317.","journal-title":"Cell Death Differ"},{"key":"632_CR76","doi-asserted-by":"publisher","first-page":"30257","DOI":"10.1074\/jbc.M109.040824","volume":"284","author":"G Brien","year":"2009","unstructured":"Brien G, Debaud A-L, Robert X, Oliver L, Trescol-Biemont M-C, Cauquil N, et al. C-terminal Residues Regulate Localization and Function of the Antiapoptotic Protein Bfl-1. J Biol Chem. 2009;284:30257\u201363.","journal-title":"J Biol Chem"},{"key":"632_CR77","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1038\/sj.onc.1206274","volume":"22","author":"J-K Ko","year":"2003","unstructured":"Ko J-K, Lee M-J, Cho S-H, Cho J-A, Lee B-Y, Koh JS, et al. Bfl-1S, a novel alternative splice variant of Bfl-1, localizes in the nucleus via its C-terminus and prevents cell death. Oncogene. 2003;22:2457\u201365.","journal-title":"Oncogene"},{"key":"632_CR78","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/sj.cdd.4400519","volume":"6","author":"SP Holmgreen","year":"1999","unstructured":"Holmgreen SP, Huang DC, Adams JM, Cory S. Survival activity of Bcl-2 homologs Bcl-w and A1 only partially correlates with their ability to bind pro-apoptotic family members. Cell Death Differ. 1999;6:525\u201332.","journal-title":"Cell Death Differ"},{"key":"632_CR79","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-2141.2008.07562.x","volume":"145","author":"M Jourdan","year":"2009","unstructured":"Jourdan M, Reme T, Goldschmidt H, Fiol G, Pantesco V, De Vos J, et al. Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells. Br J Haematol. 2009;145:45\u201358.","journal-title":"Br J Haematol"},{"key":"632_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2417-0","volume":"11","author":"ML Hartman","year":"2020","unstructured":"Hartman ML, Czyz M. BCL-w: apoptotic and non-apoptotic role in health and disease. Cell Death Dis. 2020;11:260.","journal-title":"Cell Death Dis"},{"key":"632_CR81","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3109\/00207454.2013.795149","volume":"123","author":"JP Cao","year":"2013","unstructured":"Cao JP, Niu HY, Wang HJ, Huang XG, Gao DS. NF-\u03baB p65\/p52 plays a role in GDNF up-regulating Bcl-2 and Bcl-w expression in 6-OHDA-induced apoptosis of MN9D cell. Int J Neurosci. 2013;123:705\u201310.","journal-title":"Int J Neurosci"},{"key":"632_CR82","doi-asserted-by":"publisher","first-page":"6700","DOI":"10.1523\/JNEUROSCI.0233-09.2009","volume":"29","author":"MF Pazyra-Murphy","year":"2009","unstructured":"Pazyra-Murphy MF, Hans A, Courchesne SL, Karch C, Cosker KE, Heerssen HM, et al. A retrograde neuronal survival response: target-derived neurotrophins regulate MEF2D and bcl-w. J Neurosci. 2009;29:6700\u20139.","journal-title":"J Neurosci"},{"key":"632_CR83","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.gene.2008.12.002","volume":"432","author":"A Lapham","year":"2009","unstructured":"Lapham A, Adams JE, Paterson A, Lee M, Brimmell M, Packham G. The Bcl-w promoter is activated by beta-catenin\/TCF4 in human colorectal carcinoma cells. Gene. 2009;432:112\u20137.","journal-title":"Gene"},{"key":"632_CR84","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/emboj\/cdg144","volume":"22","author":"MG Hinds","year":"2003","unstructured":"Hinds MG, Lackmann M, Skea GL, Harrison PJ, Huang DCS, Day CL. The structure of Bcl-w reveals a role for the C-terminal residues in modulating biological activity. EMBO J. 2003;22:1497\u2013507.","journal-title":"EMBO J"},{"key":"632_CR85","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1002\/1521-4141(200207)32:7<1847::AID-IMMU1847>3.0.CO;2-7","volume":"32","author":"V Ayll\u00f3n","year":"2002","unstructured":"Ayll\u00f3n V, Cayla X, Garc\u00eda A, Fleischer A, Rebollo A. The anti-apoptotic molecules Bcl-xL and Bcl-w target protein phosphatase 1alpha to Bad. Eur J Immunol. 2002;32:1847\u201355.","journal-title":"Eur J Immunol"},{"key":"632_CR86","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677\u201381.","journal-title":"Nature"},{"key":"632_CR87","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202\u20138.","journal-title":"Nat Med"},{"key":"632_CR88","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1182\/blood.2024025525","volume":"145","author":"AP Kater","year":"2025","unstructured":"Kater AP, Harrup R, Kipps TJ, Eichhorst B, Owen CJ, Assouline S, et al. The MURANO study: final analysis and retreatment\/crossover substudy results of VenR for patients with relapsed\/refractory CLL. Blood. 2025;145:2733\u201345.","journal-title":"Blood"},{"key":"632_CR89","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1182\/blood.2024024631","volume":"144","author":"O Al-Sawaf","year":"2024","unstructured":"Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink AM, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study. Blood. 2024;144:1924\u201335.","journal-title":"Blood"},{"key":"632_CR90","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791\u2013803.","journal-title":"Blood"},{"key":"632_CR91","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","volume":"7","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, et al. Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Sig Transduct Target Ther. 2022;7:51.","journal-title":"Sig Transduct Target Ther"},{"key":"632_CR92","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","volume":"104","author":"E Tausch","year":"2019","unstructured":"Tausch E, Close W, Dolnik A, Bloehdorn J, Chyla B, Bullinger L, et al. Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica. 2019;104:e434\u2013e437.","journal-title":"Haematologica"},{"key":"632_CR93","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1182\/blood.2022016090","volume":"141","author":"DM Moujalled","year":"2023","unstructured":"Moujalled DM, Brown FC, Chua CC, Dengler MA, Pomilio G, Anstee NS, et al. Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia. Blood. 2023;141:634\u201344.","journal-title":"Blood"},{"key":"632_CR94","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","volume":"36","author":"R Gui\u00e8ze","year":"2019","unstructured":"Gui\u00e8ze R, Liu VM, Rosebrock D, Jourdain AA, Hern\u00e1ndez-S\u00e1nchez M, Martinez Zurita A, et al. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell. 2019;36:369\u201384.e13.","journal-title":"Cancer Cell"},{"key":"632_CR95","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1158\/2159-8290.CD-22-0601","volume":"13","author":"C Glytsou","year":"2023","unstructured":"Glytsou C, Chen X, Zacharioudakis E, Al-Santli W, Zhou H, Nadorp B, et al. Mitophagy promotes resistance to BH3 mimetics in acute myeloid leukemia. Cancer Discov. 2023;13:1656\u201377.","journal-title":"Cancer Discov"},{"key":"632_CR96","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03497-2","volume":"20","author":"W Wei","year":"2022","unstructured":"Wei W, Huang S, Ling Q, Mao S, Qian Y, Ye W, et al. Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia. J Transl Med. 2022;20:299.","journal-title":"J Transl Med"},{"key":"632_CR97","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","volume":"18","author":"CM Rudin","year":"2012","unstructured":"Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012;18:3163\u20139.","journal-title":"Clin Cancer Res"},{"key":"632_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100056","volume":"2","author":"N Pemmaraju","year":"2025","unstructured":"Pemmaraju N, Somervaille TCP, Palandri F, Harrison C, Komrokji RS, Perkins A, et al. Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response. Blood Neoplasia. 2025;2:100056.","journal-title":"Blood Neoplasia"},{"key":"632_CR99","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13045-025-01753-8","volume":"18","author":"D Mahadevan","year":"2025","unstructured":"Mahadevan D, Barve M, Mahalingam D, Parekh J, Kurman M, Strauss J, et al. First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed\/refractory solid malignancies. J Hematol Oncol. 2025;18:98.","journal-title":"J Hematol Oncol"},{"key":"632_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112186","volume":"192","author":"X Zhang","year":"2020","unstructured":"Zhang X, Thummuri D, Liu X, Hu W, Zhang P, Khan S, et al. Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020;192:112186.","journal-title":"Eur J Med Chem"},{"key":"632_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46922-4","volume":"15","author":"D Nayak","year":"2024","unstructured":"Nayak D, Lv D, Yuan Y, Zhang P, Hu W, Nayak A, et al. Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL. Nat Commun. 2024;15:2743.","journal-title":"Nat Commun"},{"key":"632_CR102","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","volume":"31","author":"Y Ma","year":"2025","unstructured":"Ma Y, Yang Y, Huang Y, Fang W, Xue J, Meng X, et al. A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1\/1b trial. Nat Med. 2025;31:1949\u201357.","journal-title":"Nat Med"},{"key":"632_CR103","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/1078-0432.CCR-23-1525","volume":"30","author":"NJ Lakhani","year":"2024","unstructured":"Lakhani NJ, Rasco D, Wang H, Men L, Liang E, Fu T, et al. First-in-Human Study with Preclinical Data of BCL-2\/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2024;30:506\u201321.","journal-title":"Clin Cancer Res"},{"key":"632_CR104","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","volume":"10","author":"M Konopleva","year":"2006","unstructured":"Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10:375\u201388.","journal-title":"Cancer Cell"},{"key":"632_CR105","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1101\/gad.215855.113","volume":"27","author":"X Wang","year":"2013","unstructured":"Wang X, Bathina M, Lynch J, Koss B, Calabrese C, Frase S, et al. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 2013;27:1351\u201364.","journal-title":"Genes Dev"},{"key":"632_CR106","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","volume":"14","author":"H Wang","year":"2021","unstructured":"Wang H, Guo M, Wei H, Chen Y. Targeting MCL-1 in cancer: current status and perspectives. J Hematol Oncol. 2021;14:67.","journal-title":"J Hematol Oncol"},{"key":"632_CR107","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s43856-023-00380-z","volume":"3","author":"J Yuda","year":"2023","unstructured":"Yuda J, Will C, Phillips DC, Abraham L, Alvey C, Avigdor A, et al. Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients. Commun Med (Lond). 2023;3:154.","journal-title":"Commun Med (Lond)"},{"key":"632_CR108","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","volume":"26","author":"J Cidado","year":"2020","unstructured":"Cidado J, Boiko S, Proia T, Ferguson D, Criscione SW, San Martin M, et al. AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells. Clin Cancer Res. 2020;26:922\u201334.","journal-title":"Clin Cancer Res"},{"key":"632_CR109","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1182\/blood.2021013277","volume":"139","author":"AC Lewis","year":"2022","unstructured":"Lewis AC, Pope VS, Tea MN, Li M, Nwosu GO, Nguyen TM, et al. Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia. Blood. 2022;139:3737\u201351.","journal-title":"Blood"},{"key":"632_CR110","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1182\/blood-2024-202691","volume":"144","author":"DM Moujalled","year":"2024","unstructured":"Moujalled DM, Pomilio G, Morley T, Litalien V, Anstee NS, Loo S, et al. CD74 antibody conjugated to an MCL1 Inhibitor (S227928) combines synergistically with venetoclax to enhance killing of acute myeloid leukemia. Blood. 2024;144:4136.","journal-title":"Blood"},{"key":"632_CR111","doi-asserted-by":"publisher","first-page":"12424","DOI":"10.1073\/pnas.95.21.12424","volume":"95","author":"CG Print","year":"1998","unstructured":"Print CG, Loveland KL, Gibson L, Meehan T, Stylianou A, Wreford N, et al. Apoptosis regulator bcl-w is essential for spermatogenesis but appears otherwise redundant. Proc Natl Acad Sci USA. 1998;95:12424\u201331.","journal-title":"Proc Natl Acad Sci USA"},{"key":"632_CR112","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1172\/JCI89486","volume":"127","author":"CM Adams","year":"2017","unstructured":"Adams CM, Kim AS, Mitra R, Choi JK, Gong JZ, Eischen CM. BCL-W has a fundamental role in B cell survival and lymphomagenesis. J Clin Invest. 2017;127:635\u201350.","journal-title":"J Clin Invest"},{"key":"632_CR113","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","volume":"568","author":"FM Behan","year":"2019","unstructured":"Behan FM, Iorio F, Picco G, Gon\u00e7alves E, Beaver CM, Migliardi G, et al. Prioritization of cancer therapeutic targets using CRISPR\u2013Cas9 screens. Nature. 2019;568:511\u20136.","journal-title":"Nature"},{"key":"632_CR114","doi-asserted-by":"publisher","first-page":"10795","DOI":"10.1021\/acs.jmedchem.4c00291","volume":"67","author":"J Lou","year":"2024","unstructured":"Lou J, Zhou Q, Lyu X, Cen X, Liu C, Yan Z, et al. Discovery of a Covalent Inhibitor That Overcame Resistance to Venetoclax in AML Cells Overexpressing BFL-1. J Med Chem. 2024;67:10795\u2013830.","journal-title":"J Med Chem"},{"key":"632_CR115","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1038\/s41388-017-0111-1","volume":"37","author":"A Esteve-Arenys","year":"2018","unstructured":"Esteve-Arenys A, Valero JG, Chamorro-Jorganes A, Gonzalez D, Rodriguez V, Dlouhy I, et al. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1\/A1 in in vitro and in vivo models of MYC+\/BCL2+ double hit lymphoma. Oncogene. 2018;37:1830\u201344.","journal-title":"Oncogene"},{"key":"632_CR116","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","volume":"91","author":"T Tsao","year":"2012","unstructured":"Tsao T, Shi Y, Kornblau S, Lu H, Konoplev S, Antony A, et al. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol. 2012;91:1861\u201370.","journal-title":"Ann Hematol"},{"key":"632_CR117","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","volume":"26","author":"S Jin","year":"2020","unstructured":"Jin S, Cojocari D, Purkal JJ, Popovic R, Talaty NN, Xiao Y, et al. 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis. Clin Cancer Res. 2020;26:3371\u201383.","journal-title":"Clin Cancer Res"},{"key":"632_CR118","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/leu.2015.316","volume":"30","author":"S-S Chen","year":"2016","unstructured":"Chen S-S, Chang BY, Chang S, Tong T, Ham S, Sherry B, et al. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia. 2016;30:833\u201343.","journal-title":"Leukemia"},{"key":"632_CR119","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1182\/blood-2016-04-709519","volume":"128","author":"G Pavlasova","year":"2016","unstructured":"Pavlasova G, Borsky M, Seda V, Cerna K, Osickova J, Doubek M, et al. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4\/SDF-1 axis. Blood. 2016;128:1609\u201313.","journal-title":"Blood"},{"key":"632_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00429-z","volume":"11","author":"P Lu","year":"2021","unstructured":"Lu P, Wang S, Franzen CA, Venkataraman G, McClure R, Li L, et al. Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. Blood Cancer J. 2021;11:39.","journal-title":"Blood Cancer J"},{"key":"632_CR121","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","volume":"380","author":"N Jain","year":"2019","unstructured":"Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, et al. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019;380:2095\u2013103.","journal-title":"N Engl J Med"},{"key":"632_CR122","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nm.3788","volume":"21","author":"SM Chan","year":"2015","unstructured":"Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong W-J, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21:178\u201384.","journal-title":"Nat Med"},{"key":"632_CR123","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","volume":"4","author":"CA Lachowiez","year":"2023","unstructured":"Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, et al. A phase Ib\/II study of ivosidenib with venetoclax \u00b1 azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov. 2023;4:276\u201393.","journal-title":"Blood Cancer Discov"},{"key":"632_CR124","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","volume":"11","author":"FJ Kohlhapp","year":"2021","unstructured":"Kohlhapp FJ, Haribhai D, Mathew R, Duggan R, Ellis PA, Wang R, et al. Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade. Cancer Discov. 2021;11:68\u201379.","journal-title":"Cancer Discov"},{"key":"632_CR125","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1182\/blood-2024-206306","volume":"144","author":"PK Reville","year":"2024","unstructured":"Reville PK, Sajedi S, Ferrajoli A, Burger JA, Keating MJ, Garg N, et al. Atezolizumab combined with venetoclax and obinutuzumab for frontline CLL. Blood. 2024;144:1014.","journal-title":"Blood"},{"key":"632_CR126","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1182\/blood.2024027506","volume":"146","author":"N Daver","year":"2025","unstructured":"Daver N, Vyas P, Huls G, D\u00f6hner H, Maury S, Novak J, et al. The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy. Blood. 2025;146:601\u201311.","journal-title":"Blood"},{"key":"632_CR127","doi-asserted-by":"publisher","first-page":"e010073","DOI":"10.1136\/jitc-2024-010073","volume":"13","author":"H Zhang","year":"2025","unstructured":"Zhang H, Xia L, Xuzhang W, Li Z, Zhang J, Li F, et al. BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer. J Immunother Cancer. 2025;13:e010073.","journal-title":"J Immunother Cancer"},{"key":"632_CR128","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1158\/2159-8290.CD-18-1151","volume":"9","author":"SW Lok","year":"2019","unstructured":"Lok SW, Whittle JR, Vaillant F, Teh CE, Lo LL, Policheni AN, et al. A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. Cancer Discov. 2019;9:354\u201369.","journal-title":"Cancer Discov"},{"key":"632_CR129","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1158\/1078-0432.CCR-21-3811","volume":"28","author":"GJ Lindeman","year":"2022","unstructured":"Lindeman GJ, Fernando TM, Bowen R, Jerzak KJ, Song X, Decker T, et al. VERONICA: randomized phase ii study of fulvestrant and venetoclax in ER-positive metastatic breast cancer post-CDK4\/6 inhibitors - efficacy, safety, and biomarker results. Clin Cancer Res. 2022;28:3256\u201367.","journal-title":"Clin Cancer Res"},{"key":"632_CR130","doi-asserted-by":"publisher","first-page":"9511","DOI":"10.1200\/JCO.2023.41.16_suppl.9511","volume":"41","author":"Z Eroglu","year":"2023","unstructured":"Eroglu Z, Mehnert JM, Giobbie-Hurder A, Kendra KL, In GK, Salama AKS, et al. Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466). JCO. 2023;41:9511.","journal-title":"JCO"},{"key":"632_CR131","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.cell.2015.01.042","volume":"160","author":"J Montero","year":"2015","unstructured":"Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015;160:977\u201389.","journal-title":"Cell"},{"key":"632_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00333-0","volume":"6","author":"A Manzano-Mu\u00f1oz","year":"2022","unstructured":"Manzano-Mu\u00f1oz A, Yeste J, Ortega MA, Mart\u00edn F, L\u00f3pez A, Rosell J, et al. Microfluidic-based dynamic BH3 profiling predicts anticancer treatment efficacy. NPJ Precis Oncol. 2022;6:90.","journal-title":"NPJ Precis Oncol"},{"key":"632_CR133","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1182\/blood.2020008017","volume":"137","author":"N Bala Tannan","year":"2021","unstructured":"Bala Tannan N, Manzari MT, Herviou L, Da Silva Ferreira M, Hagen C, Kiguchi H, et al. Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition. Blood. 2021;137:2057\u201369.","journal-title":"Blood"},{"key":"632_CR134","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2025-453","volume":"146","author":"C Lachowiez","year":"2025","unstructured":"Lachowiez C, Kaempf A, Othman J, Yun S, Heiblig M, Heuser M, et al. Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study. Blood. 2025;146:453.","journal-title":"Blood"},{"key":"632_CR135","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1182\/blood-2025-222","volume":"146","author":"YJ Kim","year":"2025","unstructured":"Kim YJ, Furudate K, DiNardo C, Maiti A, Swaminathan M, Li Z, et al. Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia. Blood. 2025;146:222.","journal-title":"Blood"},{"key":"632_CR136","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1182\/blood-2025-341","volume":"146","author":"J Choi","year":"2025","unstructured":"Choi J, Gu L, Lee Y, Choi Y, Hong S, Choi B, et al. Mechanistic dissection of venetoclax sensitivity in AML through single-molecule BCL2 protein complex profiling and mutation-specific apoptotic rewiring. Blood. 2025;146:341.","journal-title":"Blood"},{"key":"632_CR137","doi-asserted-by":"publisher","first-page":"e96521","DOI":"10.1371\/journal.pone.0096521","volume":"9","author":"G Liu","year":"2014","unstructured":"Liu G, Poppe L, Aoki K, Yamane H, Lewis J, Szyperski T. High-quality NMR structure of human anti-apoptotic protein domain Mcl-1(171-327) for cancer drug design. PLoS ONE. 2014;9:e96521.","journal-title":"PLoS ONE"}],"container-title":["Oncogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41389-026-00632-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-026-00632-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-026-00632-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T04:02:53Z","timestamp":1786075373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41389-026-00632-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":137,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["632"],"URL":"https:\/\/doi.org\/10.1038\/s41389-026-00632-2","relation":{},"ISSN":["2157-9024"],"issn-type":[{"value":"2157-9024","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"43"}}